Tycel J. Phillips, MD, of the University of Michigan Medical School, discusses the findings of the largest retrospective study to date of patients with intravascular diffuse large B-cell lymphoma, a disease with a poor outcome, partly due to the difficulty in diagnosing it early (Abstract 377).
Jia Ruan, MD, of NewYork-Presbyterian/Weill Cornell Medical Center, discusses a 5-year follow-up analysis that showed lenalidomide and rituximab as initial treatment achieved a high rate of complete responses and MRD negativity with durable remissions beyond 4 years (Abstract 154).
Michael Unterhalt, MD, of the University Hospital Grosshadern, discusses study findings on rituximab maintenance after first-line immunochemotherapy among older patients who are not candidates for autologous stem cell transplantation (Abstract 153).
Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study results on combined venetoclax and ibrutinib for patients with previously untreated high-risk and relapsed/refractory chronic lymphocytic leukemia (Abstract 429).
Mark J. Roschewski, MD, of the National Cancer Institute, discusses phase II study findings that showed DA-EPOCH-R cures most adult patients with Burkitt lymphoma, irrespective of HIV status (Abstract 188).
John F. Seymour, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses an interim analysis of venetoclax plus rituximab vs bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (Abstract LBA-2).
